Millipore Sigma Vibrant Logo
Atención: Nos hemos mudado. Los productos Merck Millipore ya no pueden adquirirse en MerckMillipore.comMás información

344095 Fluvastatin, Sodium Salt - CAS 93957-55-2 - Calbiochem

A synthetic HMG-CoA reductase inhibitor (IC₅₀ = 40-100 nM for human liver microsomes) that acts as an anti-hypercholesterolemic agent.

Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.

Sinónimos: (±)-(3Rʹ,5Sʹ,6E)-7-[3-(4-Fluorophenyl)-1-isopropylindol-2-yl]-3,5-dihydroxy-6-heptenoate, sodium

Primary Target: HMG-CoA reductase
344095
Purchase on Sigma-Aldrich

Descripción

Replacement Information

Tabla espec. clave

CAS #Empirical Formula
93957-55-2C₂₄H₂₅FNNaO₄

Products

Número de referenciaEmbalaje Cant./Env.
344095-25MG Ampolla de plást. 25 mg
Description
OverviewA synthetic HMG-CoA reductase inhibitor (IC50 = 40-100 nM for human liver microsomes) that acts as an anti-hypercholesterolemic agent. Decreases the basal MMP-1 levels in culture media of endothelial cells in a time- and dose-dependent manner. Inhibits the formation of TBA-reactive substances in Fe(II)-supported peroxidation of liposomes (IC50 = 12 µM). Also available as a 10 mM solution in H2O(Cat. No. 344096).
Catalogue Number344095
Brand Family Calbiochem®
Synonyms(±)-(3Rʹ,5Sʹ,6E)-7-[3-(4-Fluorophenyl)-1-isopropylindol-2-yl]-3,5-dihydroxy-6-heptenoate, sodium
References
ReferencesYamamoto, A., et al. 2001. J. Pharm. Pharmacol. 53, 227.
Dansette, P.M., et al. 2000. Exp. Toxicol. Pathol. 52, 145.
Ikeda, U., et al. 2000. Hypertension 36, 325.
Levy, R.I., et al. 1993. Circulation 87 (4 Suppl.), III45.
Tse, F.L.S. et al. 1992. J. Clin. Pharmacol. 32, 630.
Yuan, J., et al. 1991. Atherosclerosis 87, 147.
Product Information
CAS number93957-55-2
ATP CompetitiveN
FormLight yellow solid
Hill FormulaC₂₄H₂₅FNNaO₄
Chemical formulaC₂₄H₂₅FNNaO₄
ReversibleN
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetHMG-CoA reductase
Primary Target IC<sub>50</sub>40-100 nM against HMG-CoA reductase in human liver microsomes
Purity≥98% by HPLC
Physicochemical Information
Cell permeableN
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
RTECSMJ9675050
Safety Information
R PhraseR: 62-63

Possible risk of impaired fertility.
Possible risk of harm to the unborn child.
S PhraseS: 22-24/25-36/37/39-45

Do not breathe dust.
Avoid contact with skin and eyes.
Wear suitable protective clothing, gloves and eye/face protection.
In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Carcinogenic / Teratogenic
Storage -20°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Número de referencia GTIN
344095-25MG 04055977215182

Documentation

Fluvastatin, Sodium Salt - CAS 93957-55-2 - Calbiochem Ficha datos de seguridad (MSDS)

Título

Ficha técnica de seguridad del material (MSDS) 

Fluvastatin, Sodium Salt - CAS 93957-55-2 - Calbiochem Certificados de análisis

CargoNúmero de lote
344095

Referencias bibliográficas

Visión general referencias
Yamamoto, A., et al. 2001. J. Pharm. Pharmacol. 53, 227.
Dansette, P.M., et al. 2000. Exp. Toxicol. Pathol. 52, 145.
Ikeda, U., et al. 2000. Hypertension 36, 325.
Levy, R.I., et al. 1993. Circulation 87 (4 Suppl.), III45.
Tse, F.L.S. et al. 1992. J. Clin. Pharmacol. 32, 630.
Yuan, J., et al. 1991. Atherosclerosis 87, 147.
Ficha técnica

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision10-January-2011 RFH
Synonyms(±)-(3Rʹ,5Sʹ,6E)-7-[3-(4-Fluorophenyl)-1-isopropylindol-2-yl]-3,5-dihydroxy-6-heptenoate, sodium
DescriptionA synthetic, competitive inhibitor of HMG-CoA reductase that acts as anti-hypercholesterolemic agent. Unlike Lovastatin (Cat. No. 438185), Mevastatin (Cat. No. 474700), and Simvastatin (Cat. No. 567020), it does not require activation prior to use for in vitro studies. Reduces the basal MMP-1 levels in culture media of endothelial cells in a time- and dose-dependent manner. Fluvastatin is metabolized in the liver, primarily via hydroxylation of the indole ring at the 5- and 6-positions. N-Dealky-lation and b-oxidation of the side-chain also occurs. The hydroxy metabolites are also reported to have some pharmacologic activity.
FormLight yellow solid
Intert gas (Yes/No) Packaged under inert gas
CAS number93957-55-2
RTECSMJ9675050
Chemical formulaC₂₄H₂₅FNNaO₄
Structure formulaStructure formula
Purity≥98% by HPLC
SolubilityH₂O (30 mg/ml), DMSO, or Methanol
Storage Protect from light
-20°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Toxicity Carcinogenic / Teratogenic
Merck USA index14, 4218
ReferencesYamamoto, A., et al. 2001. J. Pharm. Pharmacol. 53, 227.
Dansette, P.M., et al. 2000. Exp. Toxicol. Pathol. 52, 145.
Ikeda, U., et al. 2000. Hypertension 36, 325.
Levy, R.I., et al. 1993. Circulation 87 (4 Suppl.), III45.
Tse, F.L.S. et al. 1992. J. Clin. Pharmacol. 32, 630.
Yuan, J., et al. 1991. Atherosclerosis 87, 147.